This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing…

Read More
Merck (MRK) earnings Q3 2025

Merck (MRK) earnings Q3 2025

Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda. The drugmaker also narrowed its full-year profit outlook to reflect lower estimated tariff costs, among other factors. Shares of Merck fell more than 2% in premarket trading Thursday. Sales of Keytruda topped $8 billion…

Read More
FDA to speed up generic drug approvals as Trump targets drug costs

FDA to speed up generic drug approvals as Trump targets drug costs

U.S. Food and Drug Administration Commissioner Marty Makary speaks during a press conference alongside U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., and Centers for Medicare & Medicaid Services Administrator Mehmet Oz, discussing administration plans to lower drug costs, at the Department of Health and Human Services in Washington, D.C., U.S., Oct….

Read More
Eli Lilly, Nvidia to build supercomputer, AI factory for drug discovery

Eli Lilly, Nvidia to build supercomputer, AI factory for drug discovery

Eli Lilly and Nvidia are partnering to build what they call the pharmaceutical industry’s “most powerful” supercomputer and so-called AI factory to help accelerate drug discovery and development across the sector, the companies announced Tuesday.  It’s the latest stride by Nvidia and the pharmaceutical industry to harness AI to help shorten the time it takes…

Read More